Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses

Experimental monoclonal antibody (mAb) therapies have shown promise for treatment of lethal Ebola virus (EBOV) infections, but their species-specific recognition of the viral glycoprotein (GP) has limited their use against other divergent ebolaviruses associated with human disease. Here, we mined th...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cell
Autores principales: Wec, Anna Z., Herbert, Andrew S., Murin, Charles D., Nyakatura, Elisabeth K., Abelson, Dafna M., Fels, J. Maximilian, He, Shihua, James, Rebekah M., de La Vega, Marc-Antoine, Zhu, Wenjun, Bakken, Russell R., Goodwin, Eileen, Turner, Hannah L., Jangra, Rohit K., Zeitlin, Larry, Qiu, Xiangguo, Lai, Jonathan R., Walker, Laura M., Ward, Andrew B., Dye, John M., Chandran, Kartik, Bornholdt, Zachary A.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2017
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5808922/
https://ncbi.nlm.nih.gov/pubmed/28525755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cell.2017.04.037
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares